LOS ANGELES, Oct 7, 2025 – Johnson & Johnson (JNJ.N) was ordered to pay 966 million by a Los Angeles jury in a talc-related mesothelioma case, adding to mounting legal costs for the healthcare giant 1. The verdict underscores significant litigation exposure that could pressure earnings and prolonged settlement negotiations across thousands of similar claims.
- Jury awards 966 million in damages to mesothelioma victim’s family
- Verdict includes 16 million compensatory, 950 million punitive damages
- Case adds to J&J’s mounting talc litigation exposure
Verdict Details
The jury ordered Johnson & Johnson to pay 16 million in compensatory damages and 950 million in punitive damages to the family of Mae Moore, who died from mesothelioma in 2021 2. The case centered on allegations that J&J’s talc products contained asbestos and caused Moore’s cancer.
The jury found J&J liable for negligence and breach of warranty, concluding the company’s talc products, contaminated with asbestos, caused Moore’s mesothelioma 3. This represents one of the larger individual verdicts in the ongoing talc litigation saga facing the pharmaceutical company.
Legal and Financial Context
Johnson & Johnson has faced thousands of lawsuits alleging its talc-based products caused ovarian cancer and mesothelioma. The company has consistently denied these claims and maintained its products are safe and asbestos-free.
The latest verdict comes as J&J continues efforts to resolve talc litigation through bankruptcy proceedings of its subsidiary LTL Management. The company has proposed settlement amounts totaling billions of dollars to resolve current and future claims, though negotiations remain ongoing.
Market Impact
Large jury awards in product liability cases typically create uncertainty for pharmaceutical companies regarding total settlement costs. J&J’s stock has generally weathered previous talc-related verdicts, though cumulative litigation expenses have pressured margins.
The healthcare conglomerate generated 85.2 billion in revenue in 2024, with its pharmaceutical division contributing the majority of profits. Legal reserves and settlement costs related to various litigation matters remain a key earnings consideration for investors.
Corporate Response and Outlook
Johnson & Johnson typically appeals large jury verdicts and has successfully reduced or overturned several previous talc-related awards. The company maintains its products do not cause cancer and plans to continue defending against such claims.
The latest verdict adds pressure on J&J’s broader strategy to resolve talc litigation through its subsidiary’s bankruptcy process. Investors will monitor whether this outcome affects ongoing settlement negotiations or prompts changes to the proposed resolution framework.
Not investment advice. For informational purposes only.
References
1(Oct 7, 2025). “Johnson & Johnson ordered to pay 966 million after jury finds company liable in talc cancer case”. CNBC. Retrieved Oct 7, 2025.
2(Oct 7, 2025). “Johnson & Johnson ordered to pay 966 million after jury finds company liable in talc case”. Reuters. Retrieved Oct 7, 2025.
3(Sep 29, 2025). “Talc Powder Ovarian Cancer Lawsuit”. Lawsuit Information Center. Retrieved Oct 7, 2025.
4(Oct 7, 2025). “Johnson & Johnson ordered to pay 966 million after jury finds company liable”. Yahoo News. Retrieved Oct 7, 2025.
5(Oct 7, 2025). “Johnson & Johnson ordered to pay 966 million after jury finds company liable”. Westlaw Today. Retrieved Oct 7, 2025.
6(Oct 7, 2025). “Johnson & Johnson ordered to pay 966 million in talc cancer case”. Investing.com. Retrieved Oct 7, 2025.
7(Oct 7, 2025). “Johnson & Johnson Faces 966 Million Verdict in Talc-Related Cancer Lawsuit”. MarketScreener. Retrieved Oct 7, 2025.